Picture by Getty / Futurism
It looks like each week, there is a new headline in regards to the health benefits of GLP-1s, the brand new class of injectable weight reduction medicine like semaglutide, the lively ingredient in Ozempic and Wegovy.
Nonetheless, in a brand new editorial published in the Journal of Public Health Management and Practice, a gaggle of public well being specialists identified that the companies funding the research into these drugs and their security are sometimes the identical ones making billions of dollars from their runaway popularity.
Of their commentary, the Duke-led group of well being researchers recommend that there is a evident battle of curiosity when corporations like Novo Nordisk, the maker of Ozempic and Wegovy, provoke analysis into the security and efficacy of those medicine.
As these specialists level out, studies have shown that “scientific trials sponsored by pharmaceutical corporations usually tend to yield favorable outcomes for firm merchandise than unbiased trials.”
This so-called “sponsorship bias” cannot solely result in favorable tutorial papers, however comparable boosterism within the media and public notion of the medicine. The pattern is additional sophisticated as each doctors and influencers are paid to push the injections with out revealing damaging unintended effects like gastrointestinal distress.
Together with recommending that organizations just like the Nationwide Institutes of Well being fund extra goal analysis into the security of those varieties of medication, the researchers additionally mentioned that social media posts about them ought to be “flagged and accompanied by correct well being info from respected authorities” just like the NIH or FDA — like that nearly three-quarters of sufferers taking semaglutide skilled gastrointestinal issues like nausea and diarrhea.
At occasions, there appears to be pressure within the commentary’s takeaways: along with points round potential bias, the researchers additionally criticize semaglutide’s excessive value, saying it makes the drug exhausting to entry for the underserved communities who would possibly want it most.
Nonetheless, regardless of debate about whether or not exercise and diet should still be considered the gold standard in weight reduction interventions, the researchers behind the commentary mentioned that the oft-misunderstood threat components related to GLP-1s outweigh such criticisms.
“We consider that the potential threat components and uncertainties of GLP-1 receptor medicine and different pharmaceutical choices ought to render way of life interventions because the frontline therapy,” they wrote, “whereas pharmaceutical interventions ought to be supplied on a case-by-case foundation for sufferers for whom way of life modifications don’t produce lasting outcomes.”
Extra on GLP-1s: Eli Lilly Offering Way Cheaper Zepbound, If You’re Willing to Buy Your Own Syringes
